Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

No More Big Fish In A Small Pond: Yuhan Opts For Globalization For Long-Term Growth

Executive Summary

After clinching massive licensing-out agreements with multinationals last year, Yuhan is setting out a long-term global road map with a determination that it won’t just remain top in the South Korean market. The head of the firm's newly established global strategy department talks to Scrip how and why it aims to achieve globalization in the next decade and beyond.

You may also be interested in...



Korean Biopharmas Rush To Boston: What Are The Challenges And Opportunities?

The head of the US arm of a major Korean government development institute talks to Scrip about why biotechs and pharma firms are flocking to Boston, how the organization is providing support and what the main challenges are.

Korean Pharmas Race To Globalize But Tacks Vary

Although South Korean pharma firms are largely sailing toward the common goal of globalization, they have different strategies to reach their goals. Scrip takes a look at the variety of paths being pursued.

World-First Nod For Yuhan's Lung Cancer Drug, In Korea

The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC125256

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel